PLSE

Pulse BIOSCIENCES, Inc.

Healthcare · Medical Instruments & Supplies

$47.57

−$0.99−2.04%

Delayed · 2026-08-28T20:00:00.000Z · marketstack

all 7 open-market sales on file ran under a pre-arranged trading plan ($5.25M), so none was a decision taken that week. Who, and when

Aug 24, 2026$47.57

−$1.56−3.18%over 1M

Session

Day range28% of range

$47.01$49.00

Fundamentals

Visualize fundamentals and more

Market cap: 3.29B
P/E ratio: -

Risk factors, year on year

Item 1AFeb 2026 10-KMar 2025

added: 15
dropped: 16
re-drafted: 63

Out of 215 passages in this year’s Item 1A.

New this year

lack of adequate reimbursement of patient costs or lack of evidence showing that procedures using our devices are reimbursable by third party payers;

30 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed February 2026.

FDA approval
Reimbursement
Litigation
Product recalls
Goodwill impairment
Key people
Pandemic
Tariffs

And 14 more.

FDA approval
Some of these events could be the basis for FDA or other regulatory action, including injunction, recall, seizure, or total or partial suspension of production. We believe that developing the commercialization aspects of a company will take a substantial …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Recent activity

Sep 1 Teplitsky Liane Rae bought 1,001 shares Insider trading Form 4 Chief Operating Officer, about $50k
Aug 31 Teplitsky Liane Rae bought 1,024 shares Insider trading Form 4 Chief Operating Officer, about $50k
Aug 6 Results announcement Company filing 8-K

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Updated Aug 28, 2026 · the last close

Pulse BIOSCIENCES, Inc. investor relations

What PLSE has filed with the SEC. This is not Pulse BIOSCIENCES, Inc.’s own investor relations site: these filings are the primary source that site publishes from.

Companies like Pulse BIOSCIENCES, Inc.

Also filed under Medical Instruments & Supplies, ranked by how closely they sit beside PLSE.

ISRGIntuitive Surgical Inc.compare with PLSE
BDXBecton Dickinson & Co.compare with PLSE
COO

What it says it is exposed to

From Item 1A of its most recent 10-K, filed February 2026.

FDA approval
Reimbursement
Litigation
Product recalls
Goodwill impairment
Key people
Pandemic
Tariffs

And 14 more.

FDA approval
Some of these events could be the basis for FDA or other regulatory action, including injunction, recall, seizure, or total or partial suspension of production. We believe that developing the commercialization aspects of a company will take a substantial …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Cooper COMPANIES, Inc.

WSTWest Pharmaceutical Services Inc.compare with PLSE

Ask about Pulse BIOSCIENCES, Inc.

The assistant answers from what PLSE has actually filed: 11 annual reports filed with the SEC, 22 Form 4 filings from the last year and 3 funds that hold it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Press one and the answer appears right here on the page, from PLSE's filings and figures. One a day without an account; a free account has its own, and no card.

See how much of Pulse BIOSCIENCES, Inc. each of these investors holds, and every quarter they moved.

Ten seconds. No card. Nothing to cancel.

No card, no broker connection.

Continue with Google

What an account lets you do with Pulse BIOSCIENCES, Inc.

Be told the moment a PLSE insider trades
Put Pulse BIOSCIENCES, Inc. on a watchlist for a free alert, the bell and a daily email, when a Form 4 worth a row is filed, with vesting and automatic tax sales already struck out so what lands is a decision, not paperwork.
The full filing historyMeasure
Ask what growth the price is already betting on
Pulse BIOSCIENCES, Inc.'s income statement, balance sheet and cash flow as filed, and the ratios computed from them, plus a reverse DCF that holds today's price fixed and solves for the growth it requires.
The reverse DCFMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: how big a bet each one is, and by how much it changed.
Every position, sizedMeasure
Interrogate the filing, not the internet
Ask anything about Pulse BIOSCIENCES, Inc.'s fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free account See what the paid plans add

Free, no card, and it does not expire.

Recent activity

Sep 1 Teplitsky Liane Rae bought 1,001 shares Insider trading Form 4 Chief Operating Officer, about $50k
Aug 31 Teplitsky Liane Rae bought 1,024 shares Insider trading Form 4 Chief Operating Officer, about $50k
Aug 6 Results announcement Company filing 8-K

39 more events are on Measure

Free, no card, and it does not expire. See what the paid plans add

Risk factors, year on year

Item 1AFeb 2026 10-KMar 2025

added: 15
dropped: 16
re-drafted: 63

Out of 215 passages in this year’s Item 1A.

New this year

lack of adequate reimbursement of patient costs or lack of evidence showing that procedures using our devices are reimbursable by third party payers;

30 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add